Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib + nab-paclitaxel in advanced TNBC (EPIK-B3)
NCT04251533Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jun 2020
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial of alpelisib in triple-negative breast cancer (TNBC) (3 arms), sponsored by Novartis. Primary endpoints: Progression-free Survival up to 6 months and Overall Response Rate up to 35 months. Started Jun 2020; status: terminated.
02
Drugs
alpelisib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04251533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04251533.